With ties to University of Wisconsin, NeoClone Biotechnology International LLC develops and produces monoclonal antibodies for the biotechnology and research markets. It offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, markers, and interferon gamma, as well as offers cancer antibodies and Softag products. The company also provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. In addition, it provides project fast tracking, peptide or recombinant protein antigen development, tolerization, antibody purification, long-term cell line storage, mAb characterization, and additional ascites development services. NeoClone Biotechnology International was founded in 1999 and is based in Madison, Wisconsin.
